4.7 Review

mTOR: from growth signal integration to cancer, diabetes and ageing

Journal

NATURE REVIEWS MOLECULAR CELL BIOLOGY
Volume 12, Issue 1, Pages 21-35

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrm3025

Keywords

-

Categories

Funding

  1. US National Institutes of Health
  2. Howard Hughes Medical Institute
  3. Whitehead Institute for Biomedical Research
  4. Jane Coffin Childs Memorial Fund
  5. Human Frontier Science Program
  6. NATIONAL CANCER INSTITUTE [R01CA129105, R01CA103866] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047389, R37AI047389] Funding Source: NIH RePORTER

Ask authors/readers for more resources

In all eukaryotes, the target of rapamycin (TOR) signalling pathway couples energy and nutrient abundance to the execution of cell growth and division, owing to the ability of TOR protein kinase to simultaneously sense energy, nutrients and stress and, in metazoans, growth factors. Mammalian TOR complex 1 (mTORC1) and mTORC2 exert their actions by regulating other important kinases, such as S6 kinase (S6K) and Akt. In the past few years, a significant advance in our understanding of the regulation and functions of mTOR has revealed the crucial involvement of this signalling pathway in the onset and progression of diabetes, cancer and ageing.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available